Author

E. Ainsua-Enrich

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Organism:rat· 1

Frequent Co-Authors

A. Valencia· 2 shared B. Clotet· 2 shared B. Trinite· 2 shared C. Avila-Nieto· 2 shared C. Rovirosa· 2 shared E. Pradenas· 2 shared F. Tarres-Freixas· 2 shared J. Blanco· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Valencia

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.

J. Carrillo, C. Avila-Nieto, J. Vergara-Alert, P. Amengual-Rigo, E. Ainsua-Enrich, M. Brustolin, M. L. Rodriguez de la Concepcion, N. Pedreno-Lopez, J. Rodon, V. Urrea, E. Pradenas, S. Marfil, E. Ballana, E. Riveira-Munoz, M. Perez, , J. Segales

This paper identifies mutations that improve the production and efficacy of SARS-CoV-2 Spike proteins, protecting animal models from the Beta variant.

bioRxiv · Jul 7, 2023Immunology

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

E. Pradenas, B. Trinite, V. Urrea, S. Marfil, C. Avila-Nieto, M. L. Rodriguez de la Concepcion, F. Tarres-Freixas, S. Perez-Yanes, C. Rovirosa, E. Ainsua-Enrich, J. Rodon, J. Vergara-Alert, J. Sagales, V. Guallar, A. Valencia, , J. Blanco

This study tracks neutralizing antibody levels in COVID-19 patients up to six months post-infection, finding persistent activity in mild cases and a slower decline in hospitalized individuals.

bioRxiv · Nov 22, 2020Immunology